Advicenne Secures Unlimited UK Renewal for Sibnayal® in Rare Kidney Disease Treatment — Advicenne SA

Event summary

Advicenne’s Sibnayal® received unlimited renewal of its Marketing Authorization in the UK, effective June 2026.
The MHRA’s decision follows the EU’s renewal, reinforcing Sibnayal®’s role in treating distal Renal Tubular Acidosis (dRTA).
Advicenne is awaiting a September 3, 2026 FDA decision on ADV7103, its lead product candidate.
The company has secured multiple marketing authorizations for Sibnayal® across Gulf countries and recent reimbursement approvals in France.

The big picture

Advicenne’s UK renewal underscores the growing validation of Sibnayal® as a critical treatment for rare kidney diseases. The company is positioning itself as a key player in nephrology, with strategic regulatory wins and an expanding global footprint. Success in the U.S. market would further solidify its leadership in this niche therapeutic area.

What we're watching

Regulatory Momentum: Whether Advicenne can sustain this regulatory success in other key markets, particularly the U.S., following its upcoming FDA decision.
Commercial Expansion: The pace at which Advicenne expands Sibnayal®’s commercial reach beyond Europe and the Gulf into higher-value markets like the U.S.
Pipeline Progress: How Advicenne’s late-stage development of ADV7103 for cystinuria will impact its long-term growth trajectory in nephrology.